64x Bio vs Ochre Bio

<p>64x Bio provides a comprehensive software platform designed to overcome manufacturing challenges in next generation medicines. With their VectorSelect and AAV Apex Suite, they empower you to engineer high yield cell lines and optimize production technologies for gene, cell, and biologic therapies. This allows faster, scalable therapeutic manufacturing that keeps pace with scientific breakthroughs.</p> <p>The platform is tailored for biopharma companies and CDMOs aiming to scale advanced therapies efficiently. By combining computational insights and parallelized screening, 64x Bio creates optimized cell lines for lentivirus and AAV production among others. Licensing options and partnerships offer flexibility in adoption, making it a practical solution to unlock the potential of advanced therapeutics manufacturing.</p>

<p>Ochre Bio is a cutting-edge platform that combines AI with large-scale human liver data to accelerate drug discovery specifically for chronic liver diseases. It enables you to explore causal disease mechanisms, validate targets in human tissue, and develop RNA therapies in-house, significantly reducing R&amp;D timelines. The platform targets the pharmaceutical industry and research organizations aiming to find effective treatments beyond liver transplants.</p> <p>With investments in proprietary datasets and integrated gene atlases, Ochre Bio supports discovery, validation, and clinical development pipelines. You benefit from access to mechanistic insights, RNA therapeutic development, and partnerships with leading companies like GSK. This platform aims to revolutionize liver disease treatment by making drug development faster and more precise.</p>